2 February 2021

Bayer has signed an agreement with CureVac to support the manufacturing of its mRNA Covid-19 vaccine, CVnCoV,  in Germany; this expands upon an existing development and commercialisation between Bayer and CureVac. This update to the agreement occurs in the context of the need for current production capacities for Covid-19 vaccines to be increased, as Stefan Oelrich, the president of Bayer’s pharmaceutical division, announced at a press conference.

The UK Government has exercised its option to order 40 million doses of Valneva‘s inactivated, adjuvanted Covid-19 vaccine candidate in 2022. This brings the total volume of Valneva’s vaccine ordered to 100 million doses. The UK also retains the option to order an additional 90 million doses between 2023 and 2025. If all the options are exercised, the total cost of the deal is expected to total $1.69bn.

CureVac is collaborating with global contract development and manufacturing organisation (CDMO) Rentschler Biopharma to set-up manufacturing capabilities for CureVac’s Covid-19 vaccine, CVnCoV. While CureVac has begun its Phase IIb/III clinical trial of CVnCoV, Rentschler looking forward to scale-up current Good Manufacturing Practice production of the formulated mRNA for CVnCoV.

Eli Lilly has collaborated with local health systems to launch a dedicated infusion centre for north, south and central Indiana, which will help enable access to important Covid-19 treatments.  The US Food and Drug Administration has granted emergency use authorisation to multiple neutralising antibody therapies that need to administered via intravenous infusion for treating mild to moderate Covid-19 symptoms among high-risk patients.